Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease
about
Nanomedicine and drug delivery strategies for treatment of inflammatory bowel diseaseRNA interference-based nanosystems for inflammatory bowel disease therapyRecent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel diseaseHuman vascular endothelial cells reduce sphingosylphosphorylcholine-induced smooth muscle cell contraction in co-culture system through integrin β4 and FynProtection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles.STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cellsNon-condensing polymeric nanoparticles for targeted gene and siRNA deliveryEvaluation of In Vivo Transfection Efficiency of Eudragit Coated Nanoparticles of Chitosan-DNA: A pH-sensitive System Prepared for Oral DNA Delivery.Lipidoid Nanoparticles for siRNA Delivery to the Intestinal Epithelium: In Vitro Investigations in a Caco-2 Model.Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease.Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy.Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapyGlycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle.Nanomedical system for nucleic acid drugs created with the biodegradable nanoparticle platform.Recent progress in copolymer-mediated siRNA delivery.Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.Therapeutic gene delivery using bioreducible polymers.Nanotechnology in the treatment of inflammatory bowel diseases.Targeted delivery systems for biological therapies of inflammatory diseases.Nanomedicines in gastroenterology and hepatology.The application of RNAi-based treatments for inflammatory bowel disease.Polysaccharide-based micro/nanocarriers for oral colon-targeted drug delivery.Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation.Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa.Therapeutic approaches for the delivery of TNF-α siRNA.Ternary polymeric nanoparticles for oral siRNA delivery.Protein based therapeutic delivery agents: Contemporary developments and challenges.Oral nucleic acid therapy using multicompartmental delivery systems.Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery.Interleukin 34: a new modulator of human and experimental inflammatory bowel diseasePotential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.Effects of particle size and binding affinity for small interfering RNA on the cellular processing, intestinal permeation and anti-inflammatory efficacy of polymeric nanoparticles.Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy.Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.Nanotherapeutics for the treatment of inflammatory bowel disease.Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages.Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract.Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.
P2860
Q26777400-45DFF355-BC8F-40EE-AB38-439D97E9979AQ28071518-7A05FF2A-903B-4AD3-9B57-9911D796D021Q28073219-585720FC-25B5-468E-86F5-836AFD0C226CQ33567040-8854DCE7-2E9A-40D8-97D4-F1F769332BACQ33902729-73B911B4-DD26-45B0-BC0B-C2A126612593Q35031755-4B9ECBAC-5DD3-4D52-B8F1-A1F9A936E48FQ35190149-2A38432F-BA47-474C-B4A4-9B53FCB18D36Q35645058-F570A504-B57F-4717-A147-FED9E90716FEQ35698851-76FB011C-CE23-484C-BF48-AA57444F42A3Q35750016-C281BC24-2F70-4436-BF1A-941D6C428FB6Q36002746-0287F9E3-9ED8-4720-A3DE-A055D816440BQ36414624-702F3955-BCD4-45EE-AAA5-8311B26892D9Q37146028-F2D402AD-3244-4A03-A13B-A19CE7D0F8BBQ37695146-93025582-D2F3-4036-AB59-E66639CB0782Q37950418-8138E56C-2E39-41CF-8BB3-186979B2BC32Q38023545-C5FF3C7B-8F0A-4BA6-9D8E-49B4735D8F3BQ38049367-03C536FA-1E7B-4BC5-8992-1176F2C2C997Q38110619-548B1A04-B15B-4381-A1C8-0A382EFFE227Q38157750-E57CCB94-0311-4B73-A33C-6703062979DBQ38200842-87905D0F-BDF9-4574-90E0-A09226D98FA6Q38264691-4A1A367F-4789-4C72-9507-1243B3C4D81EQ38370747-607C17B5-B570-4F07-A2B4-CD8F8ADD7853Q38382964-912ADC48-2014-4770-9ED5-5992329C139BQ38696356-50FFE8F3-B0E0-4DC6-8DB9-CC84BD0B0DBBQ39162056-9497D6C2-25C5-4C5B-AFE1-6BFBBF1B74A0Q39170844-62DF0B74-17BE-4669-A5D1-18650930FCC5Q39210558-287CBDE7-28AC-43FA-90FC-5B25E6B95C84Q39212602-D8CABC99-E327-4DB0-9714-A920825DE02FQ39273739-34FDA470-4350-47C2-95AE-CCB38A5DD626Q39330117-D9EEA3E0-FB64-4557-AF36-54C6CD652EF7Q40353194-CC00C25A-EB1C-4A99-A5A5-0C1733A9DA40Q41036825-9ED42168-BAD2-41B4-843B-8546CE32E36FQ43202907-F8C2E291-4661-495D-9C3B-94319F8C9AB7Q44143118-86D7DD76-FE92-4405-B76C-7CDAC8416D38Q46272530-C51768E1-7082-49DF-A96C-212F90930F01Q47262860-C280578A-B3EF-445C-BDFF-1D52E1B8A863Q47941914-45ACFA71-FFCC-4E88-9E9D-648331D8EE75Q48020807-3B8C1110-3C56-4E06-9DD6-DB3ECD90D9BCQ48120325-7F9D1212-1FBE-4755-AACD-0535FE026EB2Q50268454-C60BCC47-14A8-469F-85C8-114DF3D07460
P2860
Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@ast
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@en
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@nl
type
label
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@ast
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@en
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@nl
prefLabel
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@ast
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@en
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@nl
P2860
P921
P1476
Oral TNF-α gene silencing usin ...... of inflammatory bowel disease
@en
P2093
Christina Kriegel
Mansoor Amiji
P2860
P356
10.1016/J.JCONREL.2010.10.002
P407
P577
2010-10-17T00:00:00Z